Literature DB >> 29749705

Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome.

Giorgio Gargari1, Valentina Taverniti1, Claudio Gardana1, Cesare Cremon2, Filippo Canducci3, Isabella Pagano2, Maria Raffaella Barbaro2, Lara Bellacosa2, Anna Maria Castellazzi4, Chiara Valsecchi5, Sara Carlotta Tagliacarne4, Massimo Bellini6, Lorenzo Bertani6, Dario Gambaccini6, Santino Marchi6, Michele Cicala7, Bastianello Germanà8, Elisabetta Dal Pont8, Maurizio Vecchi9, Cristina Ogliari9, Walter Fiore10, Vincenzo Stanghellini2, Giovanni Barbara2, Simone Guglielmetti1.   

Abstract

Irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, is classified according to bowel habits as IBS with constipation (IBS-C), with diarrhea (IBS-D), with alternating constipation and diarrhea (IBS-M), and unsubtyped (IBS-U). The mechanisms leading to the different IBS forms are mostly unknown. This study aims to evaluate whether specific fecal bacterial taxa and/or short-chain fatty acids (SCFAs) can be used to distinguish IBS subtypes and are relevant for explaining the clinical differences between IBS subcategories. We characterized five fecal samples collected at 4-weeks intervals from 40 IBS patients by 16S rRNA gene profiling and SCFA quantification. Finally, we investigated the potential correlations in IBS subtypes between the fecal microbial signatures and host physiological and clinical parameters. We found significant differences in the distribution of Clostridiales OTUs among IBS subtypes and reduced levels of SCFAs in IBS-C compared to IBS-U and IBS-D patients. Correlation analyses showed that the diverse representation of Clostridiales OTUs between IBS subtypes was associated with altered levels of SCFAs; furthermore, the same OTUs and SCFAs were associated with the fecal cytokine levels and stool consistency. Our results suggest that intestinal Clostridiales and SCFAs might serve as potential mechanistic biomarkers of IBS subtypes and represent therapeutic targets.
© 2018 Society for Applied Microbiology and John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29749705     DOI: 10.1111/1462-2920.14271

Source DB:  PubMed          Journal:  Environ Microbiol        ISSN: 1462-2912            Impact factor:   5.491


  24 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

2.  Gut microbiota alterations associated with antibody-mediated rejection after kidney transplantation.

Authors:  Junpeng Wang; Xin Li; Xiaoqiang Wu; Zhiwei Wang; Chan Zhang; Guanghui Cao; Shun Liu; Tianzhong Yan
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-24       Impact factor: 4.813

3.  Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.

Authors:  Feng Lai; Rong Jiang; Wenjun Xie; Xinrong Liu; Yong Tang; Hong Xiao; Jieying Gao; Yan Jia; Qunhua Bai
Journal:  Neurochem Res       Date:  2018-08-31       Impact factor: 3.996

4.  Distinctions Between Fecal and Intestinal Mucosal Microbiota in Subgroups of Irritable Bowel Syndrome.

Authors:  Yangfan Hou; Lei Dong; Xiaolan Lu; Haitao Shi; Bing Xu; Wenting Zhong; Lin Ma; Shuhui Wang; Caifeng Yang; Xinyi He; Yidi Zhao; Shenhao Wang
Journal:  Dig Dis Sci       Date:  2022-07-25       Impact factor: 3.487

5.  Identification of putative transcriptomic biomarkers in irritable bowel syndrome (IBS): Differential gene expression and regulation of TPH1 and SERT by vitamin D.

Authors:  Aleksandra Grozić; Keaton Coker; Christopher M Dussik; Marya S Sabir; Zhela Sabir; Arianna Bradley; Lin Zhang; Jin Park; Steven Yale; Ichiro Kaneko; Maryam Hockley; Lucinda A Harris; Tisha N Lunsford; Todd R Sandrin; Peter W Jurutka
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

6.  Prebiotics Improved the Defecation Status via Changes in the Microbiota and Short-chain Fatty Acids in Hemodialysis Patients.

Authors:  Makoto Miyoshi; Atsuko Shiroto; Hiraku Kadoguchi; Makoto Usami; Yuichi Hori
Journal:  Kobe J Med Sci       Date:  2020-04-01

7.  Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome.

Authors:  Gerardo Calderon; Chirag Patel; Michael Camilleri; Toyia James-Stevenson; Matthew Bohm; Robert Siwiec; Nicholas Rogers; John Wo; Carolyn Lockett; Anita Gupta; Huiping Xu; Andrea Shin
Journal:  J Clin Gastroenterol       Date:  2022-03-01       Impact factor: 3.062

Review 8.  The Microbiota-Gut-Brain Axis: From Motility to Mood.

Authors:  Kara G Margolis; John F Cryan; Emeran A Mayer
Journal:  Gastroenterology       Date:  2021-01-22       Impact factor: 22.682

9.  Functional Gastrointestinal Disorders and the Microbiome-What Is the Best Strategy for Moving Microbiome-based Therapies for Functional Gastrointestinal Disorders into the Clinic?

Authors:  Ruben A T Mars; Mary Frith; Purna C Kashyap
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 22.682

10.  Bacterial DNAemia is associated with serum zonulin levels in older subjects.

Authors:  Giorgio Gargari; Giacomo Mantegazza; Valentina Taverniti; Cristian Del Bo'; Stefano Bernardi; Cristina Andres-Lacueva; Raul González-Domínguez; Paul A Kroon; Mark S Winterbone; Antonio Cherubini; Patrizia Riso; Simone Guglielmetti
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.